TACSTD2 and breast neoplasm: Sacituzumab–Govitecan is an antibody–drug conjugate composed of an antibody targeting human trophoblast cell surface antigen 2 (Trop-2), expressed in most breast tumors, coupled to SN-38 (a topoisomerase I inhibitor) through a hydrolysable linker [241].